, Volume 15, Issue 5, pp 469–480 | Cite as

Clinical and Economic Outcomes of Olanzapine Compared With Haloperidol for Schizophrenia

Results From a Randomised Clinical Trial
  • Susan H. Hamilton
  • Dennis A. Revicki
  • Eric T. Edgell
  • Laura A. Genduso
  • Gary Tollefson
Original Research Article Outcomes of Olanzapine vs Haloperidol


Objective: The purpose of this study was to compare, from the payor perspective, the clinical and economic outcomes of olanzapine to those of haloperidol for the treatment of schizophrenia.

Design and setting: Clinical, quality-of-life and resource utilisation data were prospectively collected for US-residing patients with schizophrenia who were participating in a multicentre, randomised, double-blind clinical trial comparing olanzapine and haloperidol. Direct medical costs were estimated by assigning standardised prices (1995 values) to the resource utilisation data.

Patients and participants: 817 patients with schizophrenia who had a baseline Brief Psychiatric Rating Scale score (BPRS) ≥18 (items scored 0 to 6) and/or were no longer tolerating current antipsychotic therapy.

Interventions: Olanzapine 5 to 20 mg/day (n = 551) or haloperidol 5 to 20 mg/day (n = 266) for 6 weeks. Patients showing a predefined level of clinical response entered a 46-week maintenance phase.

Main outcome measures and results: After acute treatment, BPRS-based clinical improvements were seen in 38 and 27% of olanzapine and haloperidol patients, respectively (p = 0.002). Clinically important improvements on the Quality of Life Scale were achieved during acute treatment in 33% of olanzapine recipients and 25% of haloperidol recipients (p = 0.094). Olanzapine treatment in the acute phase led to significantly lower inpatient ($US5125 vs $US5795, p = 0.038) and outpatient ($US663 vs $US692, p = 0.001) costs, resulting in a significant overall reduction in mean total medical costs of $US388 (p = 0.033). This significant reduction in total costs was found despite olanzapine mean medication costs being significantly greater than haloperidol medication costs ($US326 vs $US15, p < 0.001). No significant differences in clinical improvement were observed in the maintenance phase. Maintenance phase olanzapine mean total medical costs were $US636 lower than haloperidol total costs (p = 0.128). Although olanzapine medication costs were significantly higher than haloperidol medication costs ($US3461 vs $US95, p < 0.001), this difference was offset by significantly lower inpatient ($US8322 vs $US10 662, p = 0.044) and outpatient ($US3810 vs $US5473, p = 0.038) costs.

Conclusions: In this study, olanzapine treatment was more effective than haloperidol in producing clinical response in the acute phase. In addition, olanzapine treatment led to reductions in inpatient and outpatient costs that more than offset olanzapine’s higher medication costs relative to haloperidol.


Schizophrenia Adis International Limited Haloperidol Clozapine Olanzapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bland RC, Parker JH, Orn H. Prognosis in schizophrenia: a ten-year follow-up of first admissions. Arch Gen Psychiatry 1976; 33: 949–54PubMedCrossRefGoogle Scholar
  2. 2.
    McGlashan TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14: 515–42PubMedGoogle Scholar
  3. 3.
    Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry 1978; 35: 153–5PubMedCrossRefGoogle Scholar
  4. 4.
    Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders: do suicides and accidental death solely account for this excess? Arch Gen Psychiatry 1978; 35: 1181–5PubMedCrossRefGoogle Scholar
  5. 5.
    Bromer EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GEP, editors. Textbook in psychiatric epidemiology. New York (NY): John Wiley & Sons, 1996: 283–300Google Scholar
  6. 6.
    Keith SJ, Regier DA, Rae DS. Schizophrenic disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York (NY): Free Press, 1991Google Scholar
  7. 7.
    Rice D, Miller L. The economic burden of schizophrenia. The 6th Biennial Research Conference on Economics in Mental Health; 1992 Sep 21-22; Bethesda (MD), 21–2Google Scholar
  8. 8.
    Rice D, Miller L. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of mental health economics and health policy. Vol. 1. New York (NY): John Wiley & Sons, 1996: 321–34Google Scholar
  9. 9.
    Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993; 16: 413–23PubMedGoogle Scholar
  10. 10.
    Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419–29PubMedGoogle Scholar
  11. 11.
    Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567–78PubMedGoogle Scholar
  12. 12.
    Hegerty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151: 1409–16Google Scholar
  13. 13.
    Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 105–14PubMedGoogle Scholar
  14. 14.
    Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19: 287–302PubMedGoogle Scholar
  15. 15.
    Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet 1995; 346: 820–5PubMedCrossRefGoogle Scholar
  16. 16.
    Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34–9PubMedCrossRefGoogle Scholar
  17. 17.
    Keith SJ. Pharmacologic advances in the treatment of schizophrenia. N Engl J Med 1997; 337: 851–2PubMedCrossRefGoogle Scholar
  18. 18.
    Lehman AF. Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 1996; 57 Suppl. 11: 61–7PubMedGoogle Scholar
  19. 19.
    Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997; 4: 255–71PubMedCrossRefGoogle Scholar
  20. 20.
    Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997; 22: 256–66PubMedGoogle Scholar
  21. 21.
    Revicki DA. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J Clin Psychiatry 1999; 60 Suppl. 1: 7–11PubMedGoogle Scholar
  22. 22.
    Revicki DA, Luce BR, Weschler J, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4PubMedGoogle Scholar
  23. 23.
    Meltzer H, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630–8PubMedGoogle Scholar
  24. 24.
    Frankenburg FR, Zanarini MC, Cole JO, et al. Hospitalization rates among clozapine-treated patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992; 4: 247–50CrossRefGoogle Scholar
  25. 25.
    Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261–4PubMedGoogle Scholar
  26. 26.
    Jonsson D, Wålinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199–201PubMedCrossRefGoogle Scholar
  27. 27.
    Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26PubMedGoogle Scholar
  28. 28.
    Guest JF, Hart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59–67Google Scholar
  29. 29.
    Frank RG. Clozapine’s cost-benefits [letter]. Hosp Community Psychiatry 1991; 42: 92Google Scholar
  30. 30.
    Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55 Suppl. B: 161–5PubMedGoogle Scholar
  31. 31.
    Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57 Suppl. 9: 66–76PubMedGoogle Scholar
  32. 32.
    Essock SM, Hargreaves WA, Covell NH, et al. Clozapine’s effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32 (4): 683–97PubMedGoogle Scholar
  33. 33.
    Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809–15PubMedCrossRefGoogle Scholar
  34. 34.
    Mahmoud RA, Engelhart LM, Oster G, et al. Risperidone versus conventional antipsychotics: a prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Kamuela (HA)Google Scholar
  35. 35.
    Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996; 124: 159–67PubMedCrossRefGoogle Scholar
  36. 36.
    Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–23PubMedCrossRefGoogle Scholar
  37. 37.
    Beasley CM. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Response. Neuropsychopharmacology 1997; 16: 89–90Google Scholar
  38. 38.
    Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457–65PubMedGoogle Scholar
  39. 39.
    Revicki DA, Genduso L, Hamilton S, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other related psychotic disorders: quality of life and clinical outcomes of a randomised clinical trial. Qual Life Res. In pressGoogle Scholar
  40. 40.
    Tollefson G. Long-term continuation therapy with olanzapine: New Clinical Drug Evaluation Unit (NCDEU) Program. NCDEU Meeting; 1997 May 27-30; Boca Raton (FL)Google Scholar
  41. 41.
    Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997; 46: 1571–7Google Scholar
  42. 42.
    Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1987Google Scholar
  43. 43.
    Woerner MG, Mannuza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112–7PubMedGoogle Scholar
  44. 44.
    Guy W, editor. ECDEU Assessment manual for psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare (DHEW), 1976. DHEW publication no. (ADM): 76–338Google Scholar
  45. 45.
    Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi- Health Systems, Inc., 1986Google Scholar
  46. 46.
    Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–98PubMedGoogle Scholar
  47. 47.
    International Classification of Diseases, 9th revision, Clinical Modification. 4th ed. Los Angeles (CA): Practice Management Information Corporation (PMIC), 1993Google Scholar
  48. 48.
    Finkler S. The distinction between costs and charges. Ann Intern Med 1982; 96: 102–9PubMedGoogle Scholar
  49. 49.
    Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6: 57–75PubMedCrossRefGoogle Scholar
  50. 50.
    Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996Google Scholar
  51. 51.
    Payment for part B medical and other health services. Fed Regist 1994; 59: 235Google Scholar
  52. 52.
    Reed SK, Hennessy KD, Mitchell OS, et al. A mental health capitation program. II: cost-benefit analysis. Hosp Community Psychiatry 1994; 45: 1097–103PubMedGoogle Scholar
  53. 53.
    Dwyer DS, Mitchell OS, Cole R, et al. Evaluating mental health capitation treatment: lessons from panel data. Cambridge (MA): National Bureau of Economic Research, 1995Google Scholar
  54. 54.
    US Bureau of Labor Statistics. CPI detailed report. Washington, DC: US Bureau of Labor Statistics, Department of Labor, 1995Google Scholar
  55. 55.
    Palmer CS, Revicki DA, Halpern MT, et al. The cost of suicide and suicide attempts in the United States. Clin Neuropharmacol 1995; 18 Suppl. 3: S25–33CrossRefGoogle Scholar
  56. 56.
    National Association of Psychiatric Health Systems. Trends in psychiatric health systems: 1995 annual survey, final report. Washington, DC: National Association of Psychiatric Health Systems, 1995Google Scholar
  57. 57.
    Physicians GenRx. 5th ed. St. Louis (MO): Mosby-Year Book, 1995Google Scholar
  58. 58.
    Red Book pharmacy’s fundamental reference. Montville (NJ): Medical Economics Data Production Company, 1995Google Scholar
  59. 59.
    Glazer W, Ershefsky L. A pharmacoeconomic model of outpatient neuroleptic therapy in ‘revolving door’ schizophrenic patients. J Clin Psychiatry 1996; 57 (8): 337–45PubMedGoogle Scholar
  60. 60.
    Rutten-Van Molken MPMH, Van Doorslaer EKA, Van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994; 3: 333–45CrossRefGoogle Scholar
  61. 61.
    Anderson KH, Mitchell JM. Expenditures on services for persons with acquired immunodeficiency syndrome under a Medicaid home and community-based waiver program: are selection effects important? Med Care 1997; 35 (5): 425–39PubMedCrossRefGoogle Scholar
  62. 62.
    Manning WG, Newhouse JP, Duan N, et al. Health insurance and the demand for medical care. Am Econ Rev 1987; 77: 251–77PubMedGoogle Scholar
  63. 63.
    SAS Institute, Inc. SAS/STAT user’s guide. Vols. 1 & 2. 4th ed. Version 6. Cary (NC): SAS Institute, Inc., 1990Google Scholar
  64. 64.
    Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984; 5: 115–28PubMedCrossRefGoogle Scholar
  65. 65.
    Obenchain RL, Johnstone BM. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Inf J 1999; 33: 191–209CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 1999

Authors and Affiliations

  • Susan H. Hamilton
    • 1
  • Dennis A. Revicki
    • 2
  • Eric T. Edgell
    • 1
  • Laura A. Genduso
    • 3
  • Gary Tollefson
    • 1
  1. 1.Lilly Research LaboratoriesEli Lilly and Company, Lilly Corporate CenterIndianapolisUSA
  2. 2.MEDTAP InternationalBethesdaUSA
  3. 3.Medicina ConsultingIndianapolisUSA

Personalised recommendations